大阪大学 · 医学
秋山篤成教授の研究室は、腎細胞癌（RCC）をはじめとする悪性腫瘍の免疫微小環境とがん治療の予後予測因子を解明することを主眼としています。特にT細胞の機能的状態（例：PD-1+/TIM-3+のクロスエクスプレッション）や腫瘍関連マクロファージの役割、ならびに臨床的バイオマーカー（ナトリウム、CRP、好中球数など）の意義を、遺伝子発現解析や臨床的疫学的手法を用いて統合的に解析しています。治療耐性や予後との関連を解明することで、個別化医療の実現に貢献することを目指しています。
Figures are computed from collected data and may differ slightly.
Although further study is needed, ERCC1 expression level may predict the efficacy of CRT for MIBC.
It is important to evaluate the clinical importance of both CD8 T cells and CD4 T cells expression simultaneously because they have crucial networks in tumour targeting immune responses. In 97 RCC patients, RNA sequencing and gene set enrichment analysis of both CD8 and CD4 T cells based on the expression levels of PD-1 and TIM-3 implied that the populations of PD-1+TIM-3+ CD8 T cells and PD-1lowTIM-3 + CD4 T cells were characterized as exhausted CD8 T cells and regulatory CD4 T cells, respectiv
Hyponatremia (<138 mEq/L), neutrophilia and high C-reactive protein levels seem to represent significant predictive factors for cancer-specific survival in metastatic renal cell carcinoma patients treated with molecular targeted therapy as first line therapy. Furthermore, hyponatremia might be significantly associated with chronic inflammation and tumor aggressiveness.
Sorafenib was effective in Japanese patients with advanced renal cell carcinoma in general clinical practice and was tolerated although most patients required dose reduction or interruption of therapy. Future studies should establish new strategies for treatment without sacrificing both efficacy and patient quality of life.
The expression of CD4+CD8+ T cells was significantly up-regulated in RCC patients and correlated significantly with prognostic importance in surgically treated RCC patients.
Open papers in the app to read, cite, and organize with AI.
